QLD Biotherapeutics Inc

QLD biotherapeutic located in Boston, Massachusetts with over 24,000 SF state-of-the-art labs and facilities. We have a R&D team focusing on the research and development of advanced cell and gene therapies using innovative technologies to treat devastating diseases, such as cancer and neurodegenerative diseases. At same time, we provide the platform to connect and support the innovation and entrepreneurship, and we offer entrepreneurs and startup companies with venture capital investment, suitable laboratory/office space /infrastructure, and access to the company’s research expertise. We are looking for the breakthrough biotechnologies/innovative products for in-licensing, investment/incubation, or collaboration. QLD biotherapeutic is funded by Qilu Pharmaceutical, which is a leading pharmaceutical company in China (around top 5 in China) with a focus on the R&D (2 R&D sites in China and 3 R&D sites in US), manufacturing (10 sites), sales and marketing of pharmaceutical and health products. We have over 36,000 employees globally, including 3,000 R&D scientists and over 600 clinical development FTE. We have over 40 scientific leaders with education and work experience in the US at Pfizer, Amgen, Roche, Takeda, Johnson & Johnson, Merck and Genentech, etc., and over 200 pipeline products and projects including more than 80 innovative programs and 30 biologics programs, 9 IND filings in 2021(US, China, Australia). In 2021 pandemic year, we achieved $5.2 billion in the revenue and significant annual investment in R&D. Qilu Pharmaceutic is actively looking for clinical assets/technologies to develop in China’s market, also looking for out-licensing partners for Qilu’s 16 clinical stage pipelines in global markets.

Industry

Biotechnology Research

Company size

11-50 employees

Headquarters

Boston, Massachusetts

Type

Privately Held

Founded

2021

Specialties

cell and gene therapy, Incubator, AAV Gene therapy, and NK Cell therapy